Literature DB >> 21755300

Clinical significance of discordant positive hepatitis C virus transcription-mediated amplification following end of treatment response.

Anisha Thadani1, Jennifer Harley, Jonah Rubin, Edward Lebovics.   

Abstract

BACKGROUND: Polymerase chain reaction (PCR) assays are the standard for detecting hepatitis C virus viremia. The transcription-mediated amplification (TMA)-based assay is more sensitive.
METHODS: We retrospectively reviewed the charts of patients with a post-end of treatment (EOT) PCR-/TMA+ result to assess the clinical significance of a positive TMA result after a PCR negative EOT response or sustained viral response (SVR). Patients were divided into Group 1: PCR-/TMA+ after EOT response but during 24 week follow-up (n = 4); and Group 2: PCR-/TMA+ after SVR (n = 11).
RESULTS: All Group 1 patients achieved SVR. No Group 2 patients became PCR positive or had a rise in ALT. The TMA subsequently became negative in 6/7 patients with follow-up evaluation.
CONCLUSIONS: A discordant positive TMA post-EOT response or SVR did not seem to be clinically significant. This finding supports the possibility that patients with SVR have an acquired immune surveillance that prevents low-level viremia from progressing to clinical relapse.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21755300     DOI: 10.1007/s10620-011-1820-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  10 in total

1.  Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment.

Authors:  L Comanor; F Anderson; M Ghany; R Perrillo; E J Heathcote; C Sherlock; I Zitron; D Hendricks; S C Gordon
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

2.  Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays.

Authors:  C Sarrazin; G Teuber; R Kokka; H Rabenau; S Zeuzem
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

Review 3.  Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance.

Authors:  Christoph Sarrazin
Journal:  J Clin Virol       Date:  2002-12       Impact factor: 3.168

4.  Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses.

Authors:  Naga Suresh Veerapu; Sukanya Raghuraman; T Jake Liang; Theo Heller; Barbara Rehermann
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

5.  HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.

Authors:  Chihiro Morishima; Timothy R Morgan; James E Everhart; Elizabeth C Wright; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; Anna S F Lok; Herbert L Bonkovsky; Adrian M Di Bisceglie; William M Lee; Jules L Dienstag; Marc G Ghany; David R Gretch
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

6.  Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a.

Authors:  C Sarrazin; D A Hendricks; F Sedarati; S Zeuzem
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

7.  Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.

Authors:  Martina Gerotto; Francesca Dal Pero; Gladis Bortoletto; Alessia Ferrari; Roberta Pistis; Giada Sebastiani; Stefano Fagiuoli; Stefano Realdon; Alfredo Alberti
Journal:  J Hepatol       Date:  2005-09-21       Impact factor: 25.083

8.  Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin.

Authors:  Jaydeep S Kadam; Stevan A Gonzalez; Furqaan Ahmed; Alia Menezes; Ira M Jacobson
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

9.  Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.

Authors:  Chihiro Morishima; Timothy R Morgan; James E Everhart; Elizabeth C Wright; Minjun C Apodaca; David R Gretch; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; William M Lee; Anna S F Lok; Jules L Dienstag; Marc G Ghany; Teresa M Curto
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

10.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.